Upon learning more about biosimilars and the FDA’s current task of approving the use of these new medications, survey respondents expressed overwhelming support for patient safeguards.

More than 92 percent of seniors want drug companies to test the safety of biosimilars for all conditions they will be used to treat, and 86 percent want human clinical trials to take place.
— Thair Phillips, president of RetireSafe